Gastroenterology

Intelligent Scopes Launches Helga AI-GEP™, an AI Platform for Gastroenterology with the Commencement of Validation of its AI Software Tool for Colon Cancer

Retrieved on: 
Monday, March 4, 2024

NEW YORK and LONDON, March 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, specializing in state-of-the-art image enhancement and precision AI software solutions for gastroenterology and urology, is pleased to announce the completion of its AI platform for gastroenterology, namely, Helga AI-GEP™.

Key Points: 
  • NEW YORK and LONDON, March 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, specializing in state-of-the-art image enhancement and precision AI software solutions for gastroenterology and urology, is pleased to announce the completion of its AI platform for gastroenterology, namely, Helga AI-GEP™.
  • The platform will offer computer aided devices for detection, classification and characterization of lesions and tissue irregularities in the colon (colon cancer) and the upper gastrointestinal tract (esophageal and gastric cancer).
  • Validation is commencing with its AI software tool, namely, Helga iCAP™ for the detection of colonic conditions.
  • As such, Intelligent Scopes collaborates with key stakeholders including clinicians, academia, and equipment manufacturers to provide tools that can aid endoscopists in providing optimal care to patients.

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Retrieved on: 
Tuesday, February 27, 2024

This data underscores the significant impact gynecologists have in the early detection and prevention efforts against CRC.

Key Points: 
  • This data underscores the significant impact gynecologists have in the early detection and prevention efforts against CRC.
  • The Gynecology Congress is a premier event dedicated to gynecological health, offering Mainz Biomed an invaluable opportunity to connect with these vital healthcare providers.
  • This effort is aimed at increasing brand awareness and establishing ColoAlert® as a key component in medical practices for CRC screening.
  • In the coming months, Mainz Biomed will continue to actively participate in medical conferences that cater to its key demographic.

Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, February 22, 2024

WALTHAM, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • During the fourth quarter of 2023, IBSRELA U.S. net product sales revenue was $28.1 million, reflecting 26% growth compared to the third quarter of 2023.
  • Ardelyx currently expects full-year 2024 U.S. net product sales revenue for IBSRELA to be between $140.0 and $150.0 million.
  • U.S. net product sales revenue in the fourth quarter of 2023 were $2.5 million.
  • U.S. net product sales revenue in 2023 for XPHOZAH was $2.5 million following its commercial launch in November 2023.

ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART

Retrieved on: 
Tuesday, February 20, 2024

This breakthrough test, in development for nearly five years, is nearing completion of clinical studies.

Key Points: 
  • This breakthrough test, in development for nearly five years, is nearing completion of clinical studies.
  • If the clinical trial results are successful, the Company will be aiming for commercial launch during 2024.
  • Recently, an additional 139 specimens were analyzed in collaboration with The Mayo Clinic, for the purposes of assessing the test's precision and reliability in identifying esophageal adenocarcinoma risk.
  • - The test has demonstrated molecular precision in excess of 99%1, which is a remarkably precise accomplishment in cancerous tissue analysis.

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, March 5, 2024

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates.
  • From launch through year-end 2023, there were 2,833 completed prescription enrollment forms received for VOWST, of those 2,015 resulted in new patient starts by year-end 2023.
  • Strong adoption of VOWST since commercial launch in June 2023 with broad utilization, continued quarter over quarter growth, and significant progress achieving patient access.
  • General and administrative expenses for the fourth quarter of 2023 were $17.2 million, compared with $22.4 million for the same period in 2022.

New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap

Retrieved on: 
Friday, March 1, 2024

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new survey showing patients and physicians overwhelmingly agree that blood-based testing could help close the colorectal cancer (CRC) screening gap by offering a more pleasant and convenient option.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new survey showing patients and physicians overwhelmingly agree that blood-based testing could help close the colorectal cancer (CRC) screening gap by offering a more pleasant and convenient option.
  • The survey polled 1,000 American adults age 45-84, along with 351 physicians (250 primary care providers and 101 gastroenterologists).
  • In the United States, CRC screening guidelines recommend that all people of average risk begin screening starting at age 45.
  • Ultimately, 96% of all physicians surveyed would recommend an FDA-approved blood test to their patients for CRC screening.

Neurenati Therapeutics Concludes a 1.2 Million $ Seed Financing Round to Develop NEU-001 as a Promising Therapy for Hirschsprung Disease

Retrieved on: 
Thursday, February 29, 2024

Neurenati Therapeutics is delighted to announce the successful closing of its seed funding round, securing 1.2 million $ from Genson Capital, on the 2024 Rare Disease Day.

Key Points: 
  • Neurenati Therapeutics is delighted to announce the successful closing of its seed funding round, securing 1.2 million $ from Genson Capital, on the 2024 Rare Disease Day.
  • Neurenati, a Québec-based biotech company, focuses on the development of various rare diseases therapies, including pediatric conditions.
  • Maxime Ranger, President and CEO of Neurenati Therapeutics commented, “Currently, surgery remains the only option to newborns with HSCR.
  • As fourth member of the Board, he joins Rodolphe Soret (cofounder), Benoit Doré (Axelys), and Maxime Ranger (Neurenati).

Zcube Launches the 2024 Edition of Open Accelerator, an International Acceleration Program Aimed at Life Sciences Startups with Focus on Women's Health and Femtech

Retrieved on: 
Wednesday, February 28, 2024

Zcube - Zambon Research Venture announces the fifth edition of Open Accelerator, the international acceleration program for high-potential innovative startups in the field of life sciences.

Key Points: 
  • Zcube - Zambon Research Venture announces the fifth edition of Open Accelerator, the international acceleration program for high-potential innovative startups in the field of life sciences.
  • Starting this year, the program will focus on the femtech sector and will feature a new format.
  • The targeted therapeutic areas include gynecology, cardiovascular health, oncology, sexual health, endocrinology, gastroenterology, nutrition, autoimmune disorders, mental health, neurology, reproductive health, and more.
  • The Call for application will open on Friday, March 8, 2024, on the International Women's Day, and will remain open until June 16.

2024 IBS Awareness Month: The IBS Dilemma

Retrieved on: 
Thursday, March 7, 2024

MOUNT PLEASANT, S.C., March 7, 2024 /PRNewswire/ -- Irritable bowel syndrome (IBS) affects up to 5-10% of individuals worldwide, making it one of the most common gastrointestinal disorders. Although IBS does not shorten a person's life span, living with IBS presents a myriad of challenges that can significantly impact one's quality of life. From navigating social situations to managing work responsibilities, individuals with IBS constantly face dilemmas that others may not fully comprehend. This April, for IBS Awareness Month, IFFGD highlights how crucial it is to shed light on the profound dilemmas and challenges individuals living with this often-misunderstood condition may face.

Key Points: 
  • This April, for IBS Awareness Month, IFFGD highlights how crucial it is to shed light on the profound dilemmas and challenges individuals living with this often-misunderstood condition may face.
  • This year, help IFFGD and the community raise awareness, promote understanding, and offer compassion to those living with IBS.
  • You can also join IFFGD's awareness campaign by sharing information from the IBS Awareness Month Media Toolkit .
  • Learn more about IBS, visit www.aboutIBS.org or www.youandibs.org to learn about IBS through and animated video series.

Calyx and Invicro agree to combine to create a global leader in medical imaging and software solutions for the clinical research community

Retrieved on: 
Thursday, March 7, 2024

This complementary combination will create a new global leader in the provision of medical imaging solutions and development services to the clinical research community.

Key Points: 
  • This complementary combination will create a new global leader in the provision of medical imaging solutions and development services to the clinical research community.
  • The enlarged Group ("Group") formed through this strategic combination will see 100% of Invicro being acquired by Calyx from its current owner, REALM IDx, Inc.
  • The transaction is subject to regulatory filings and customary closing conditions and is expected to complete in Q2 2024.
  • Calyx and Invicro each provide complementary services to most of the world's leading pharma and biotechnology companies.